The PyroGlutamate-amyloid-beta (PyroGlu-Aβ) programme includes novel antibodies (BAN1503 and BAN2803). These target a truncated, pyroglutamate modified form of amyloid-beta. BAN2803 utilises a technology platform that optimises biologic drug delivery past the blood brain barrier, BioArctic noted.
Under the agreement, BioArctic will receive a $100 million, up to $1.25 billion in milestone payments as well as royalties on worldwide product sales.